Back to Results

Oramed Pharmaceuticals Inc (ORMP)

Oramed Pharmaceuticals Inc. is a NASDAQ-listed common stock company focused on pharmaceutical research and development. The company is working on a technology platform designed to deliver therapeutic proteins orally, rather than through conventional injection-based methods. Its lead candidate, ORMD-0801, is an oral insulin capsule being evaluated in phase III clinical trials for people with diabetes. Oramed also has license agreements with Oravax Medical Inc. covering the commercialization of oral vaccines for COVID-19 and other novel coronaviruses. Founded in 2002, the company is headquartered in New York, New York.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NASDAQ-ORMP
$5.78
21.8% Upside
Undervalued
$7
47.4% Upside
Undervalued
Great
5.3%
November 16, 2026
1.1x
0.6x
197.6 M
125.8 M
0.4%
76.4%
2.2
6.0%
-3.0%
Valuation • Fair Value

Oramed Pharmaceuticals Inc (NASDAQ-ORMP) Fair Value by Valuation Model

Review the available estimates for Oramed Pharmaceuticals Inc (NASDAQ-ORMP), including Ben Graham Formula Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$5.78

Estimated upside of 21.8% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

Ben Graham Formula Value

$46.43

Classic Ben Graham valuation formula reference.

Comps Fair Value

$5.78

Comparable-company valuation reference.

Analyst Price Target

$7

Analysts imply upside of 47.4%.

How to read these valuation models

Use the 5 available valuation references for Oramed Pharmaceuticals Inc (NASDAQ-ORMP) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Oramed Pharmaceuticals Inc (NASDAQ-ORMP)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

0 K

Current operating scale indicator.

Revenue Forecast

4 M

Forward revenue estimate.

EBITDA

-14.402 M

Current operating profitability reference.

EBITDA Forecast

-20 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Oramed Pharmaceuticals Inc (NASDAQ-ORMP) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Oramed Pharmaceuticals Inc (NASDAQ-ORMP)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Great

Positive financial-health read.

Piotroski Score

5

Mid-range quality score.

Altman Z-Score

2.2

Intermediate risk zone.

FCF / Net Income

-3.0%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Oramed Pharmaceuticals Inc (NASDAQ-ORMP). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Oramed Pharmaceuticals Inc (NASDAQ-ORMP)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 16, 2026

Days to Earnings

55

Dividend Yield

5.3%

Current income yield reference.

Payout Ratio

6.0%

Dividend payout reference.

How to read events and dividends

This section helps investors track time-sensitive items for Oramed Pharmaceuticals Inc (NASDAQ-ORMP), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Technical Outlook

Technical Signals by Time Frame

Review the technical signals currently available for this stock across supported time frames.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Neutral

The 15-minute technical read for Oramed Pharmaceuticals Inc (NASDAQ-ORMP) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Buy

The 1-hour technical read for Oramed Pharmaceuticals Inc (NASDAQ-ORMP) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Neutral

The daily technical read for Oramed Pharmaceuticals Inc (NASDAQ-ORMP) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for Oramed Pharmaceuticals Inc (NASDAQ-ORMP) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Buy

The monthly technical read for Oramed Pharmaceuticals Inc (NASDAQ-ORMP) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

FAQ • Fast Investor Answers

Oramed Pharmaceuticals Inc (NASDAQ-ORMP) Stock FAQ

Data-supported answers about Oramed Pharmaceuticals Inc (NASDAQ-ORMP), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$5.78
Estimated upside 21.8%
Valuation Rating
Undervalued
Estimated upside of 21.8%
Analyst Target
$7
Implied upside 47.4%
Financial Health
Great
Current financial-health read

The current fair value estimate for Oramed Pharmaceuticals Inc (NASDAQ-ORMP) is $5.78. This implies an estimated upside of 21.8% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 21.8% versus the current market price.

The available analyst price target for Oramed Pharmaceuticals Inc (NASDAQ-ORMP) is $7. The analyst target implies estimated upside of 47.4%.

The current financial health read for Oramed Pharmaceuticals Inc (NASDAQ-ORMP) is Great. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Oramed Pharmaceuticals Inc (NASDAQ-ORMP) is November 16, 2026.

Based on the current data, dividend yield is 5.3%.

The current P/E ratio listed for Oramed Pharmaceuticals Inc (NASDAQ-ORMP) is 1.1x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Oramed Pharmaceuticals Inc is 197.6 M.

The current enterprise value listed for Oramed Pharmaceuticals Inc is 125.8 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Oramed Pharmaceuticals Inc is NASDAQ-ORMP, and the stock is listed on NASDAQ.

Oramed Pharmaceuticals Inc (NASDAQ-ORMP) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Oramed Pharmaceuticals Inc is 0.4%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Oramed Pharmaceuticals Inc is 76.4%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

LLY NYSE Eli Lilly and Company Fair Value Fair Market Cap 1,043 B
JNJ NYSE Johnson & Johnson Fair Value Fair Market Cap 648.7 B
MRK NYSE Merck & Company Inc Fair Value Fair Market Cap 372.3 B
NVS NYSE Novartis AG ADR Fair Value Fair Market Cap 269.8 B
NVO NYSE Novo Nordisk A/S Fair Value Bargain Market Cap 175.3 B
PFE NYSE Pfizer Inc Fair Value Fair Market Cap 159.2 B
BMY NYSE Bristol-Myers Squibb Company Fair Value Fair Market Cap 127.2 B
SNY NASDAQ Sanofi ADR Fair Value Undervalued Market Cap 102 B
GSK NYSE GSK plc DRC Fair Value Undervalued Market Cap 101.9 B
TAK NYSE Takeda Pharmaceutical Co Ltd ADR Fair Value Fair Market Cap 60.536 B
TEVA NYSE Teva Pharma Industries Ltd ADR Fair Value Fair Market Cap 46.053 B
HLN NYSE HALEON PLC ADR Fair Value Fair Market Cap 40.268 B
RPRX NASDAQ Royalty Pharma Plc Fair Value Fair Market Cap 33.639 B
ZTS NYSE Zoetis Inc Fair Value Bargain Market Cap 30.107 B
VTRS NASDAQ Viatris Inc Fair Value Undervalued Market Cap 19.733 B
JAZZ NASDAQ Jazz Pharmaceuticals PLC Fair Value Fair Market Cap 15.616 B
CORT NASDAQ Corcept Therapeutics Incorporated Fair Value Overvalued Market Cap 12.702 B
ELAN NYSE Elanco Animal Health Fair Value Fair Market Cap 11.456 B
AXSM NASDAQ Axsome Therapeutics Inc Fair Value Fair Market Cap 10.639 B
RDY NYSE Dr. Reddy’s Laboratories Ltd ADR Fair Value Fair Market Cap 10.564 B